ARCT
Arcturus Therapeutics Holdings Inc

5,504
Mkt Cap
$233.85M
Volume
318,943.00
52W High
$24.17
52W Low
$5.85
PE Ratio
-3.34
ARCT Fundamentals
Price
$8.23
Prev Close
$8.32
Open
$8.15
50D MA
$7.19
Beta
1.75
Avg. Volume
501,224.60
EPS (Annual)
-$3.00
P/B
1.00
Rev/Employee
$786,301.14
$194.71
Loading...
Loading...
News
all
press releases
Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of +1.21% and -8.73%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2d ago
News Placeholder
More News
News Placeholder
Arcturus Therapeutics (ARCT) Expected to Post Earnings on Tuesday
Arcturus Therapeutics (NASDAQ:ARCT) will be releasing its Q4 2025 earnings after the market closes on Tuesday, March 3. (View Earnings Report at...
MarketBeat·4d ago
News Placeholder
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Rating of "Moderate Buy" by Brokerages
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) has been assigned an average rating of "Moderate Buy" from the thirteen ratings firms that are currently covering the stock...
MarketBeat·6d ago
News Placeholder
Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Crosses Below Two Hundred Day Moving Average - What's Next?
Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Passes Below 200-Day Moving Average - Should You Sell...
MarketBeat·10d ago
News Placeholder
Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026
Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics...
Business Wire·11d ago
News Placeholder
Arcturus Therapeutics Spotlights Inhaled mRNA CF Phase 2b Plan, FDA Talks for OTC Program at Summit
Arcturus Therapeutics (NASDAQ:ARCT) used a presentation at Guggenheim's 2026 Emerging Outlook Biotech Summit to highlight upcoming milestones for its messenger RNA (mRNA) rare disease pipeline, with...
MarketBeat·17d ago
News Placeholder
Arcturus Therapeutics (NASDAQ:ARCT) Shares Pass Below Two Hundred Day Moving Average - Time to Sell?
Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Passes Below 200 Day Moving Average - Should You Sell...
MarketBeat·22d ago
News Placeholder
Arcturus Therapeutics (NASDAQ:ARCT) Shares Cross Below 200-Day Moving Average - Here's Why
Arcturus Therapeutics (NASDAQ:ARCT) Share Price Crosses Below 200-Day Moving Average - What's Next...
MarketBeat·22d ago
News Placeholder
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the thirteen research firms that are covering the...
MarketBeat·1mo ago
News Placeholder
Arcturus Therapeutics Maps Near-Term Milestones for CF mRNA Therapy, ARCT-810 at J.P. Morgan Conference
Arcturus Therapeutics (NASDAQ:ARCT) CEO and President Joe Payne outlined the company's current focus on messenger RNA (mRNA) therapeutics, emphasizing a leaner operating profile and a near-term set...
MarketBeat·2mo ago
<
1
2
...
>

Latest ARCT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.